Collagenase clostridium histolyticum injection for the treatment of Dupuytren's contracture

Drugs of Today

Volumn 47, Issue 9, 2011, Pages 653-667

  Kaplan, F Thomas D ^a  

^a Indiana Hand Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUXILIN; CLOPIDOGREL; CLOSTRIDIOPEPTIDASE A; COLLAGEN BINDING PROTEIN; COLLAGEN FIBRIL; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 3; COLLAGEN TYPE 4; DAUNORUBICIN; DOXORUBICIN; FIBRILLAR COLLAGEN; PLACEBO; TETRACYCLINE; WARFARIN;

ANTIBACTERIAL ACTIVITY; APPLICATION SITE VESICLE; ARTHRALGIA; BLISTER; BLOOD SAMPLING; CLOSTRIDIUM HISTOLYTICUM; CLOSTRIDIUM PERFRINGENS; COLLAGEN DEGRADATION; COMPLEX REGIONAL PAIN SYNDROME; CONTUSION; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DUPUYTREN CONTRACTURE; ECCHYMOSIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; EXTRACELLULAR MATRIX; EXTRAVASATION; FIBROBLAST; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEMATOMA; HUMAN; IMMUNE RESPONSE; INJECTION SITE BLEEDING; INJECTION SITE EDEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INTERPHALANGEAL JOINT; JOINT SWELLING; LACERATION; LYMPH NODE PAIN; LYMPHADENOPATHY; MAST CELL DEGRANULATION; METACARPOPHALANGEAL JOINT; MYOFIBROBLAST; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PARESTHESIA; PERIPHERAL EDEMA; PEYRONIE DISEASE; REVIEW; SINGLE DRUG DOSE; TENDON RUPTURE; TENSILE STRENGTH; TREATMENT RESPONSE; URINALYSIS; WOUND HEALING;

ANIMALS; CLOSTRIDIUM HISTOLYTICUM; DRUG INTERACTIONS; DUPUYTREN CONTRACTURE; HUMANS; INJECTIONS, INTRALESIONAL; MICROBIAL COLLAGENASE; TREATMENT OUTCOME;

EID: 80053932345     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.9.1656502     Document Type: Review

References (34)

1. Ross, D.C. Epidemiology of Dupuytren's disease. Hand Clinics, 15(1): 53-62, vi.
2. Van Rissen, A., Linden, H., Werker, P. 5-year results of first-ever randomized clinical trial on treatment in Dupuytren's disease: percutaneous needle fasciotomy versus limited fasciectomy. Intl Symp Dupuytren's Dis (May 22-23, Miami) 2010.
3. Bassot, M. Traitement de la maladie de Dupuytren par exerese pharmacodynamique isolee ou completee par un temps plastique uniquement cutane. Lille Chir 1965, 20: 38-44.
4. Hueston, J.T. Enzymic fasciotomy. Hand 1971, 3(1): 38-40.
5. McCarthy, D.M. The long-term results of enzymic fasciotomy. J Hand Surg Br 1992, 17(3): 356.
6. Starkweather, K.D., Lattuga, S., Hurst, L.C. et al. Collagenase in the treatment of Dupuytren's disease: An in vitro study. J Hand Surg Am 1996, 21(3): 490-5. (Pubitemid 26166850)
7. Mandl, I., Columbia University, College of Physicians and Surgeons, Dept. of Biochemistry. Collagenase. Gordon and Breach: New York, 1972.
8. Gelbard, M.K., Walsh, R., Kaufman, J.J. Collagenase for Peyronie's disease experimental studies. Urol Res 1982, 10(3): 135-40. (Pubitemid 12046996)
9. Brickley-Parsons, D., Glimcher, M., Smith, R., Albin, R., Adams, J. Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren's disease. J Bone Joint Surg Am 1981, 63(5): 787-97. (Pubitemid 11127664)
10. Bisson, M.A., Mudera, V., McGrouther, D.A., Grobbelaar, A.O. The contractile properties and responses to tensional loading of Dupuytren's disease-derived fibroblasts are altered: a cause of the contracture? Plast Reconstr Surg 2004, 113(2): 611-21. (Pubitemid 39201931)
11. Murrell, G.A., Francis, M.J., Bromley, L. The collagen changes of Dupuytren's contracture. J Hand Surg Br 1991, 16(3): 263-6.
12. Maclennan, J.D., Mandl, I., Howes, E.L. Bacterial digestion of collagen. J Clin Invest 1953, 32(12): 1317-22.
13. Van Wart, H.E., Steinbrink, D.R. Complementary substrate specificities of class I and class II collagenases from Clostridium histolyticum. Biochemistry 1985, 24(23): 6520-6. (Pubitemid 16207125)
14. Auxilium Pharmaceuticals, Inc. Briefing Document for Collagenase Clostridium Histolyticum (AA4500) in the Treatment of Advanced Dupuytren's Disease. Arthritis Advisory Committee Meeting: September 16, 2009.
15. Toyoshima, T., Matsushita, O., Minami, J., Nishi, N., Okabe, A., Itano, T. Collagen-binding domain of a Clostridium histolyticum collagenase exhibits a broad substrate spectrum both in vitro and in vivo. Connect Tissue Res 2001, 42(4): 281-90. (Pubitemid 33138550)
16. Jung, C.M., Matsushita, O., Katayama, S., Minami, J., Sakurai, J., Okabe, A. Identification of metal ligands in the Clostridium histolyticum ColH collagenase. J Bacteriol 1999, 181(9): 2816-22. (Pubitemid 29211098)
17. Wilson, J.J., Matsushita, O., Okabe, A., Sakon, J. A bacterial collagen-binding domain with novel calcium-binding motif controls domain orientation. EMBO J 2003, 22(8): 1743-52. (Pubitemid 36460131)
18. Badalamente, M.A., Hurst, L.C., Hentz, V.R. Collagen as a clinical target: Nonoperative treatment of Dupuytren's disease. J Hand Surg Am 2002, 27(5): 788-98.
19. Sottrup-Jensen, L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem 1989, 264(20): 11539-42. (Pubitemid 19185316)
20. Del Carlo, M., Cole, A.A., Hart, S.G.E., Levine, L.A. Comparative analysis of collagen degradation in Peyronie's disease plaque and Dupuytren's contracture cord tissues injected with mixed collagenase subtypes. J Urol [Annu Meet Am Urol Assoc (AUA) (April 25-30, Chicago) 2009] 2009, 181(4, Suppl. 1): Abst 780.
21. Golub, L.M., Lee, H.M., Ryan, M.E., Giannobile, W.V., Payne, J., Sorsa, T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998, 12(2): 12-26.
22. Tanaka, T., Metori, K., Mineo, S., Matsumoto, H., Satoh, T. [Studies on collagenase inhibitors. III. Inhibitory effects of anthracyclines on bacterial collagenase]. Yakugaku Zasshi 1991, 111(1): 70-2.
23. Hurst, L.C., Badalamente, M.A., Hentz, V.R. et al. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med 2009, 361(10): 968-79.
24. Buczko, W., Dziaczkowski, J., Kopec, M. et al. Biological effects of degradation products of collagen by bacterial collagenase. Br J Pharmacol 1980, 69(4): 551-4. (Pubitemid 10034731)
25. Wize, J., Wojtecka-Lukasik, E., Maslinski, S. Collagen-derived peptides release mast cell histamine. Agents Actions 1986, 18(1-2): 262-5. (Pubitemid 16113272)
26. Rydevik, B., Ehira, T., Linder, L., Olmarker, K., Romanus, M., Branemark, P.I. Microvascular response to locally injected collagenase. An experimental investigation in hamsters and rabbits. Scand J Plast Reconstr Surg Hand Surg 1989, 23(1): 17-21. (Pubitemid 19132672)
27. Radice, M., Brun, P., Bernardi, D., Fontana, C., Cortivo, R., Abatangelo, G. Clostridial collagenase releases bioactive fragments from extracellular matrix molecules. J Burn Care Rehabil 1999, 20(4): 282-91. (Pubitemid 29340652)
28. Badalamente, M.A., Hurst, L.C. Enzyme injection as nonsurgical treatment of Dupuytren's disease. J Hand Surg Am 2000, 25(4): 629-36. (Pubitemid 30602565)
29. Gilpin, D., Coleman, S., Hall, S., Houston, A., Karrasch, J., Jones, N. Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease. J Hand Surg Am 2010, 35(12): 2027-38 e1.
30. Bois, A.J., Johnston, G., Classen, D. Spontaneous flexor tendon ruptures of the hand: case series and review of the literature. J Hand Surg Am 2007, 32(7): 1061-71. (Pubitemid 47362534)
31. Suomalainen, K., Sorsa, T., Golub, L.M. et al. Specificity of the anticollagenase action of tetracyclines: relevance to their anti-inflammatory potential. Antimicrob Agents Chemother 1992, 36(1): 227-9.
32. Smith, G.N., Jr., Mickler, E.A., Hasty, K.A., Brandt, K.D. Specificity of inhibition of matrix metalloproteinase activity by doxycycline: relationship to structure of the enzyme. Arthritis Rheum 1999, 42(6): 1140-6. (Pubitemid 29268950)
33. Bols, M., Binderup, L., Hansen, J., Rasmussen, P. Inhibition of collagenase by aranciamycin and aranciamycin derivatives. J Med Chem 1992, 35(15): 2768-71.
34. Auxilium Pharmaceuticals, Inc. XIAFLEX™ (collagenase clostridium histolyticum) for injection, for intralesional use, Label. February 2, 2010.